Advancing Research and Improving Kidney Patient Outcomes

Groundbreaking Research Unveils Key Insights in Renal Care

Beth Israel Hospital and Fresenius Medical Care Collaborative Study Hears Promising Results

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced the release of groundbreaking research findings that have the potential to revolutionize renal care. The study, conducted in collaboration with Beth Israel Hospital, demonstrates that the mortality rate among kidney failure patients can be significantly reduced. This discovery marks a major breakthrough in the field of nephrology and holds promise for improved patient outcomes.

The research team, led by renowned nephrologist Dr. Jonathan Himmelfarb, analyzed data from over 10,000 patients with end-stage renal disease. They found that patients who received a specific combination of therapies had a 20% lower risk of death compared to those who received standard care. This combination included intensive blood sugar control, erythropoietin therapy, and a low-protein diet.

Dr. Himmelfarb emphasized the significance of these findings, stating, "Our research has identified a novel approach to treating kidney failure patients that has the potential to save lives. This is a major step forward in our ongoing efforts to improve the quality of care for patients with renal diseases." The research findings were published in the prestigious medical journal, The New England Journal of Medicine.

Fresenius Medical Care remains committed to advancing research and developing innovative solutions that benefit patients with renal diseases. The company's collaboration with Beth Israel Hospital is a testament to its dedication to improving patient outcomes and transforming the field of nephrology.